Tower Research Capital LLC (Trc) Arvinas, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.29 Billion
Q1 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Arvinas, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 984 shares of ARVN stock, worth $6,582. This represents 0.0% of its overall portfolio holdings.

Number of Shares

984

Previous 8,305 88.15%

Holding current value

$6,582

Previous $159,000 96.23%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.02 - $20.5 $51,393 - $150,080	-7,321 Reduced 88.15%	984 $6,000
Q4 2024 Feb 13, 2025	SELL	$17.83 - $28.04 $4,617 - $7,262	-259 Reduced 3.02%	8,305 $159,000
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $67,454 - $93,313	2,851 Added 49.9%	8,564 $210,000
Q2 2024 Aug 13, 2024	BUY	$24.46 - $40.4 $118,533 - $195,778	4,846 Added 558.94%	5,713 $152,000
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $213,114 - $306,431	-5,858 Reduced 87.11%	867 $35,000
Q4 2023 Feb 13, 2024	BUY	$14.19 - $42.33 $46,358 - $138,292	3,267 Added 94.48%	6,725 $276,000
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $118,291 - $169,908	-6,023 Reduced 63.53%	3,458 $67,000
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $90,722 - $131,220	4,175 Added 78.68%	9,481 $235,000
Q1 2023 May 09, 2023	BUY	$26.15 - $37.26 $50,626 - $72,135	1,936 Added 57.45%	5,306 $145,000
Q4 2022 Feb 10, 2023	SELL	$32.47 - $57.24 $89,844 - $158,383	-2,767 Reduced 45.09%	3,370 $115,000
Q3 2022 Nov 10, 2022	BUY	$41.87 - $57.99 $141,394 - $195,832	3,377 Added 122.36%	6,137 $273,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $84,011 - $173,201	2,333 Added 546.37%	2,760 $117,000
Q1 2022 May 12, 2022	SELL	$60.27 - $81.57 $11,632 - $15,743	-193 Reduced 31.13%	427 $29,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $81,456 - $119,011	-1,237 Reduced 66.61%	620 $51,000
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $77,884 - $114,773	-1,064 Reduced 36.43%	1,857 $153,000
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $207,948 - $289,854	-3,440 Reduced 54.08%	2,921 $225,000
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $300,493 - $471,834	5,164 Added 431.41%	6,361 $421,000
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $305,696 - $1.29 Million	-15,141 Reduced 92.67%	1,197 $102,000
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $310,479 - $490,771	13,505 Added 476.7%	16,338 $386,000
Q2 2020 Aug 13, 2020	BUY	$29.88 - $56.74 $84,650 - $160,744	2,833 New	2,833 $95,000
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $7,359 - $12,153	-223 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$15.39 - $44.38 $30,333 - $87,472	-1,971 Reduced 89.84%	223 $9,000
Q3 2019 Nov 05, 2019	BUY	$21.55 - $27.61 $47,280 - $60,576	2,194 New	2,194 $47,000
Q2 2019 Aug 13, 2019	SELL	$15.96 - $23.8 $4,963 - $7,401	-311 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$13.55 - $23.79 $7,750 - $13,607	-572 Reduced 64.78%	311 $5,000
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $9,880 - $16,388	883 New	883 $11,000

Others Institutions Holding ARVN

# of Institutions

246

Shares Held

62.5M

Call Options Held

2.65M

Put Options Held

1.1M

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $356M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Arvinas, Inc. Transaction History